Oncology pipeline: research, clinical trials and treatments

We are committed to transforming the lives of people with cancer through innovative therapies. Our robust pipeline spans cancer cell–directed and immuno-oncology investigational therapies. Through global collaboration, we are tackling some of the most challenging, but potentially most impactful, areas of cancer research.

Latest development phase

Filter by:

• Development phase
  • Phase I
  • Phase II
  • Phase III

Cancer cell–directed

zongertinib (HER2 TKI) 1–11

• Zongertinib: Phase I
  • Phase I
  • Active, not recruiting

Solid tumors (Phase Ia) and NSCLC (Phase Ib)
(Recruiting for cohorts 7 and 8 only)

• Zongertinib: Phase II
  • Phase II*
  • Recruiting

NSCLC, solid tumors, breast cancer, gastric adenocarcinoma, GEJ adenocarcinoma and esophageal adenocarcinoma
± combination

• Zongertinib: Phase III

  • Phase III
  • Recruiting

  NSCLC

T-cell engagers

obrixtamig (DLL3/CD3 T-cell engager) 12–21

• DLL3/CD3 T-cell engager – obrixtamig: Phase I
  • Phase I†
  • Recruiting

SCLC and other NECs
± combination

• DLL3/CD3 T-cell engager – obrixtamig: Phase II
  • Phase II
  • Recruiting

epNEC

• DLL3/CD3 T-cell engager – obrixtamig: Phase III
  • Phase III
  • Recruiting

SCLC and epNEC

B7-H6/CD3 T-cell engager 22,23

• B7-H6/CD3 T-cell engager: Phase I
  • Phase I
  • Recruiting

Solid tumors, colorectal carcinoma, gastric carcinoma and PDAC ± combination

Oncolytic viruses

VSV-GP oncolytic virus 24

• VSV-GP oncolytic virus: Phase I
  • Phase I
  • Recruiting

Solid tumors ± combination

Immuno-modulators

CD137xFAP bsAb 25,26

• CD137 FAP bispecific agonist antibody: Phase I
  • Phase I
  • Active, not recruiting (Phase Ib)

Solid tumors and HNSCC
± combination

• SIRPα Antagonist
  • Phase I
  • Recruiting

Solid tumors and HNSCC
(Recruiting for Phase Ib) ± combination

• 2nd generation STING agonist
  • Phase I
  • Recruiting

Solid tumors

• combination

• Immunological fusion protein
  • Phase I
  • Recruiting

Solid tumors

• ezabenlimab (PD-1 inhibitor) 14,22,24,26,27,30
• ezabenlimab: Phase I
  • Phase I†
  • Recruiting

Solid tumors, PDAC, SCLC and other NECs

• combination

Download a summary of ongoing clinical trials

• Download

References

• Heymach JV, et al. J Clin Oncol 2025;43(11):1337–1347.
• Heymach JV, et al. N Engl J Med 2025;392(23):2321–2333.
• ClinicalTrials.gov. NCT04886804. https://clinicaltrials.gov/study/NCT04886804 (Accessed: May 2026).
• ClinicalTrials.gov. NCT06151574. https://clinicaltrials.gov/study/NCT06151574 (Accessed: April 2026).
• ClinicalTrials.gov. NCT06581432. https://clinicaltrials.gov/study/NCT06581432 (Accessed: April 2026).
• Schram AM, et al. J Clin Oncol 2025;43(16_suppl). Abstract TPS3187.
• ClinicalTrials.gov. NCT06324357. https://clinicaltrials.gov/study/NCT06324357 (Accessed: April 2026).
• Nakayama I, et al. J Clin Oncol 2025;43(4_suppl). Abstract TPS509.
• Hurvitz SA, et al. ESMO Open 2025;10(S4). Abstract 409TiP.
• ClinicalTrials.gov. NCT07486817. https://clinicaltrials.gov/study/NCT07486817 (Accessed: April 2026).
• ClinicalTrials.gov. NCT07195695. https://clinicaltrials.gov/study/NCT07195695 (Accessed: April 2026).
• ClinicalTrials.gov. NCT04429087. https://clinicaltrials.gov/study/NCT04429087 (Accessed: April 2026).
• Wermke M, et al. J Clin Oncol 2025;43(27):3021–3031.
• ClinicalTrials.gov. NCT05879978. https://clinicaltrials.gov/study/NCT05879978 (Accessed: April 2026).
• ClinicalTrials.gov. NCT05882058. https://clinicaltrials.gov/study/NCT05882058 (Accessed: April 2026).
• ClinicalTrials.gov. NCT06132113. https://clinicaltrials.gov/study/NCT06132113 (Accessed: April 2026).
• ClinicalTrials.gov. NCT06077500. https://clinicaltrials.gov/study/NCT06077500 (Accessed: April 2026).
• ClinicalTrials.gov. NCT05990738. https://clinicaltrials.gov/study/NCT05990738 (Accessed: April 2026).
• Wermke M, et al. ASCO 2025. Poster 8094.
• ClinicalTrials.gov. NCT07544654. https://clinicaltrials.gov/study/NCT07544654 (Accessed: May 2026).
• ClinicalTrials.gov. NCT07472517. https://clinicaltrials.gov/study/NCT07472517 (Accessed: April 2026).
• ClinicalTrials.gov. NCT06091930. https://clinicaltrials.gov/study/NCT06091930 (Accessed: April 2026).
• ClinicalTrials.gov. NCT06882746. https://clinicaltrials.gov/study/NCT06882746 (Accessed: April 2026).
• ClinicalTrials.gov. NCT05155332. https://clinicaltrials.gov/study/NCT05155332 (Accessed: April 2026).
• Shroff RT, et al. Cancer Res 2025;85(8_Supplement_2). Abstract CT110.
• ClinicalTrials.gov. NCT04958239. https://clinicaltrials.gov/study/NCT04958239 (Accessed: April 2026).
• ClinicalTrials.gov. NCT05327946. https://clinicaltrials.gov/study/NCT05327946 (Accessed: April 2026).
• Wang JS, et al. J Clin Oncol 2025;43(16_suppl). Abstract 2515.
• ClinicalTrials.gov. NCT06806852. https://clinicaltrials.gov/study/NCT06806852 (Accessed: April 2026).
• ClinicalTrials.gov. NCT05471856. https://clinicaltrials.gov/study/NCT05471856 (Accessed: April 2026).
• ClinicalTrials.gov. NCT07224425. https://clinicaltrials.gov/study/NCT07224425 (Accessed: April 2026).

bsAb, bispecific antibody; CD, cluster of differentiation; DLL3, delta-like ligand 3; epNEC, extrapulmonary neuroendocrine carcinoma; FAP, fibroblast activation protein; GEJ, gastroesophageal junction; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; HNSCC, head and neck squamous cell carcinoma; NEC, neuroendocrine carcinoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein-1; PDAC, pancreatic ductal adenocarcinoma; SCLC, small cell lung cancer; SIRPα, signal-regulatory protein alpha; STING, small molecule agonist of the stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.